Antibodies for Biodefense

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2011 Nov 30

PMID 22123065

Citations 36

Authors

Jeffrey W Froude

Bradley Stiles

Thibaut Pelat

Philippe Thullier

Affiliations

Soon will be listed here.

Abstract

Potential bioweapons are biological agents (bacteria, viruses, and toxins) at risk of intentional dissemination. Biodefense, defined as development of therapeutics and vaccines against these agents, has seen an increase, particularly in the US following the 2001 anthrax attack. This review focuses on recombinant antibodies and polyclonal antibodies for biodefense that have been accepted for clinical use. These antibodies aim to protect against primary potential bioweapons, or category A agents as defined by the Centers for Disease Control and Prevention (Bacillus anthracis, Yersinia pestis, Francisella tularensis, botulinum neurotoxins, smallpox virus, and certain others causing viral hemorrhagic fevers) and certain category B agents. Potential for prophylactic use is presented, as well as frequent use of oligoclonal antibodies or synergistic effect with other molecules. Capacities and limitations of antibodies for use in biodefense are discussed, and are generally applicable to the field of infectious diseases.

Citing Articles

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B.

Jiang Y, Wang R, Guo J, Cheng K, Chen L, Wang X Front Immunol. 2024; 15:1380694.

PMID: 38779676 PMC: 11109933. DOI: 10.3389/fimmu.2024.1380694.

Functional epitopes and neutralizing antibodies of vaccinia virus.

Peng F, Hu N, Liu Y, Xing C, Luo L, Li X Front Microbiol. 2023; 14:1255935.

PMID: 37954238 PMC: 10634548. DOI: 10.3389/fmicb.2023.1255935.

Centaur antibodies: Engineered chimeric equine-human recombinant antibodies.

Rosenfeld R, Alcalay R, Zvi A, Ben-David A, Noy-Porat T, Chitlaru T Front Immunol. 2022; 13:942317.

PMID: 36059507 PMC: 9437483. DOI: 10.3389/fimmu.2022.942317.

Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.

Henrique I, Sacerdoti F, Ferreira R, Henrique C, Amaral M, Piazza R Front Cell Infect Microbiol. 2022; 12:825856.

PMID: 35223548 PMC: 8866733. DOI: 10.3389/fcimb.2022.825856.

Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Roth K, Wenzel E, Ruschig M, Steinke S, Langreder N, Heine P Front Cell Infect Microbiol. 2021; 11:697876.

PMID: 34307196 PMC: 8294040. DOI: 10.3389/fcimb.2021.697876.

References

Rotz L, Khan A, Lillibridge S, Ostroff S, Hughes J . Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002; 8(2):225-30. PMC: 2732458. DOI: 10.3201/eid0802.010164. View

Nowakowski A, Wang C, Powers D, Amersdorfer P, Smith T, Montgomery V . Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002; 99(17):11346-50. PMC: 123259. DOI: 10.1073/pnas.172229899. View

Galimand M, Carniel E, Courvalin P . Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother. 2006; 50(10):3233-6. PMC: 1610074. DOI: 10.1128/AAC.00306-06. View

Boles J, Pitt M, LeClaire R, Gibbs P, Ulrich R, Bavari S . Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule. Vaccine. 2003; 21(21-22):2791-6. DOI: 10.1016/s0264-410x(03)00222-6. View

Adekar S, Mark Jones R, Elias M, Al-Saleem F, Root M, Simpson L . Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods. 2008; 333(1-2):156-66. DOI: 10.1016/j.jim.2008.01.015. View

Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D . High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother. 2007; 51(8):2758-64. PMC: 1932538. DOI: 10.1128/AAC.01528-06. View

Hughes J . Preserving the lifesaving power of antimicrobial agents. JAMA. 2011; 305(10):1027-8. DOI: 10.1001/jama.2011.279. View

Lou J, Geren I, Garcia-Rodriguez C, Forsyth C, Wen W, Knopp K . Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010; 23(4):311-9. PMC: 2841544. DOI: 10.1093/protein/gzq001. View

Krakauer T, Buckley M . Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob Agents Chemother. 2005; 50(1):391-5. PMC: 1346818. DOI: 10.1128/AAC.50.1.391-395.2006. View

10.

Smith T, Hill K, Foley B, Detter J, Munk A, Bruce D . Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 2007; 2(12):e1271. PMC: 2092393. DOI: 10.1371/journal.pone.0001271. View

11.

Ulrich R, Olson M, Bavari S . Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine. 1998; 16(19):1857-64. DOI: 10.1016/s0264-410x(98)00176-5. View

12.

Boles J, Pitt M, LeClaire R, Gibbs P, Torres E, Dyas B . Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol. 2003; 108(1):51-9. DOI: 10.1016/s1521-6616(03)00066-4. View

13.

Henderson D . The looming threat of bioterrorism. Science. 1999; 283(5406):1279-82. DOI: 10.1126/science.283.5406.1279. View

14.

Guo J, Shen B, Feng J, Sun Y, Yu M, Hu M . A novel neutralizing monoclonal antibody against cell-binding polypeptide of ricin. Hybridoma (Larchmt). 2005; 24(5):263-6. DOI: 10.1089/hyb.2005.24.263. View

15.

Leffel E, Reed D . Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror. 2004; 2(3):186-91. DOI: 10.1089/bsp.2004.2.186. View

16.

Inglesby T, OToole T, Henderson D, Bartlett J, Ascher M, Eitzen E . Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002; 287(17):2236-52. DOI: 10.1001/jama.287.17.2236. View

17.

Mattix M, Hunt R, Wilhelmsen C, Johnson A, Baze W . Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta). Toxicol Pathol. 1995; 23(3):262-8. DOI: 10.1177/019262339502300304. View

18.

Huzella L, Buckley M, Alves D, Stiles B, Krakauer T . Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: a new mouse model. Res Vet Sci. 2008; 86(2):241-7. DOI: 10.1016/j.rvsc.2008.07.020. View

19.

Chen Z, Moayeri M, Crown D, Emerson S, Gorshkova I, Schuck P . Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun. 2009; 77(9):3902-8. PMC: 2738033. DOI: 10.1128/IAI.00200-09. View

20.

Lowell G, Colleton C, Frost D, Kaminski R, Hughes M, Hatch J . Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun. 1996; 64(11):4686-93. PMC: 174432. DOI: 10.1128/iai.64.11.4686-4693.1996. View